Clinical Trials and Drug Development - The company is conducting Phase IIa clinical trials for the drug Paenagabin, with a target enrollment of 36 cases, which has been fully achieved at a 100% completion rate. Preliminary data shows promising therapeutic effects [2][3] - The Phase II data for Paenagabin is expected to be unblinded and results read out by the end of 2025 [2][3] - The Phase II clinical research for another drug, Fluorofenone, has completed subject enrollment and data cleaning, with results expected to be revealed by the end of this year [3][4] - Preparations for the Phase III clinical trials of Fluorofenone are underway, anticipated to start between the end of this year and early next year [3][4] Market Expansion and Partnerships - The company is actively seeking international partners for the commercialization of innovative drugs, with future expansion dependent on the Phase II clinical results of Paenagabin [3][4] - A strategic cooperation agreement has been signed with Malaysia's Aikang International Group to introduce high-quality health products and promote traditional Chinese medicine products in the Malaysian market [3][4] Product Development and Focus Areas - The company plans to focus on the neuropsychiatric field, introducing a long-acting injection for the treatment of schizophrenia, thereby forming a product cluster in this area [4] - The company aims to expand its gastrointestinal product line, particularly the Gut Health series, targeting grassroots medical institutions and increasing user base [4] - There is a commitment to deepen collaborations with universities and research institutions to enhance competitiveness in high-end formulations [4] Risk Management - There are uncertainties regarding the success of subsequent clinical trials for innovative drugs and the potential for obtaining approval from the National Medical Products Administration [4] - The company emphasizes the importance of timely information disclosure regarding the progress of innovative drugs and encourages investors to make cautious decisions [4]
海南海药(000566) - 2025年9月17日投资者关系活动记录表